Search Results

One-Year SPIRIT Small-Vessel Data Support Abbott Vascular's Xience Nano

October 1, 2012—Results from the SPIRIT Small-Vessel (SV) study were published by Louis A. Cannon, MD, et al in Catheterization and Cardiovascular Interventions (2012;80:546–553). SPIRIT SV  was designed to evaluate the safety and effectiveness of the 2.25-mm Xience V (Xience Nano, Abbott Vascular, Santa Clara, CA) everolimus-eluting coronary stent system in patients with small vessels and ischemic heart disease.

PERSEUS Data Support Boston Scientific's Taxus Element in Diabetic Patients

September 22, 2010—Boston Scientific Corporation (Natick, MA) announced results from an analysis of 1,166 patients from its PERSEUS clinical program comparing the performance of the Taxus Element paclitaxel-eluting coronary stent system in diabetic versus nondiabetic patients.

AVS Raises Financing to Advance Its Pulsatile Intravascular Lithotripsy Solutions

January 5, 2023—AVS announced that it raised $20 million in Series B financing.

FDA Approves Boston Scientific's Ion PtCr Stent System

April 25, 2011—Boston Scientific Corporation (Natick, MA) announced US Food and Drug Administration (FDA) approval and the launch of the Ion paclitaxel-eluting platinum chromium (PtCr) coronary stent system. The Ion stent will be available with sizes ranging in diameter from 2.25 to 4 mm and lengths from 8 to 38 mm, and includes both monorail and over-the-wire versions.

FDA Approves New Lengths for Boston Scientific's Promus Element Plus

June 4, 2012—Boston Scientific Corporation (Natick, MA) announced US Food and Drug Administration approval and the United States market launch of 32-mm and 38-mm lengths for the Promus Element Plus everolimus-eluting platinum chromium coronary stent system.